Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent Within Daily Clinical Practice III-Italy
Phase of Trial: Phase IV
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms Bio flow-III Satellite; BIOFLOW-III
- Sponsors BIOTRONIK
- 25 Sep 2018 Results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 28 Sep 2017 Status changed from active, no longer recruiting to completed.
- 08 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.